Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Marker Therapeutics, Inc.

  • Anthony Kim, Marker Therapeutics, Inc.

Marker Therapeutics, Inc is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit.

  • Date:Monday, February 11
  • Time:3:45 PM - 4:00 PM
  • Room:Hudson/Empire
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Submission ID:23582
  • Goal for Presentation:Outreach
  • Company Website:www.markertherapeutics.com
  • Company HQ City:Houston
  • Company HQ State:Texas
  • Company HQ Country:United States
  • Ticker:MRKR
  • Exchange:Nasdaq
  • Year Founded:2018
  • Main Therapeutic Focus:Immunology
  • Lead Product in Development:MultiTAA
  • Development Phase of Primary Product:Phase I
Speakers
Anthony Kim
Marker Therapeutics, Inc.
Back